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Clinical Science
Aim:	To	demonstrate	the	role	of	autophagy	and	incretins	on	fructose‐induced	
alteration	in	β‐cell	mass	and	function.	Methods:	Normal	Wistar	rats	were	fed	(3	
weeks)	with	commercial	diet	without	(C)	or	with	10%	fructose	in	drinking	water	(F)	
alone	or	plus	sitagliptin	(CS	and	FS)	or	exendin‐4	(CE	and	FE).	Serum	levels	of	
metabolic/endocrine	parameters,	β‐cell	mass,	morphology/ultrastructure	and	
apoptosis,	VMP1	expression	and	glucose‐stimulated	insulin	secretion	(GSIS)	were	
studied.	Complementary,	islets	isolated	from	normal	rats	were	cultured	(3	days)	
without	(C)	or	with	F	and	F	plus	exendin‐4	(FE)	or	chloroquine	(FCQ).	Expression	of	
autophagy	related‐proteins	(VMP1	and	LC3),	apoptotic/antiapoptotic	markers	
(caspase‐3	and	Bcl‐2),	GSIS	and	insulin	mRNA	levels	were	measured.	Results:	F	rats	
developed	impaired	glucose	tolerance	(IGT)	and	a	significant	increase	in	plasma	
triglyceride,	TBARS,	insulin	levels,	HOMAIR	and	HOMA‐β	indexes.	Significant	β‐cell	
mass	reduction	was	associated	to	an	increased	apoptotic	rate	and	
morphological/ultrastructural	changes	indicative	of	autophagic	activity.	All	these	
changes	were	prevented	by	either	sitagliptin	or	exendin‐4.	In	cultured	islets,	F	
significantly	enhanced	insulin	mRNA	and	GSIS,	decreased	Bcl‐2	mRNA	levels	and	
increased	caspase‐3	expression.	Chloroquine	reduced	these	changes	
suggesting	autophagy	participation	in	this	process.	Indeed,	F	induced	the	increase	of	
both,	VMP1	expression	and	LC3‐II,	suggesting	that	VMP1‐related	autophagy	is	
activated	in	injured	β‐cell.	Exendin‐4	prevented	islet‐cell	damage	and	autophagy	
development.	Conclusions:	VMP1‐related	autophagy	is	a	reactive	process	against	F‐
induced	islet	dysfunction,	being	prevented	by	exendin‐4	treatment.	This	knowledge	
could	help	to	use	autophagy	as	potential	target	for	preventing	progression	from	IGT	
toT2DM.	
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ABSTRACT 
Aim: To demonstrate the role of autophagy and incretins on fructose-induced alteration 
in β-cell mass and function. Methods: Normal Wistar rats were fed (3 weeks) with 
commercial diet without (C) or with 10% fructose in drinking water (F) alone or plus 
sitagliptin (CS and FS) or exendin-4 (CE and FE). Serum levels of metabolic/endocrine 
parameters, β-cell mass, morphology/ultrastructure and apoptosis, VMP1 expression 
and glucose-stimulated insulin secretion (GSIS) were studied. Complementary, islets 
isolated from normal rats were cultured (3 days) without (C) or with F and F plus 
exendin-4 (FE) or chloroquine (FCQ). Expression of autophagy related-proteins (VMP1 
and LC3), apoptotic/antiapoptotic markers (caspase-3 and Bcl-2), GSIS and insulin 
mRNA levels were measured. Results: F rats developed impaired glucose tolerance 
(IGT) and a significant increase in plasma triglyceride, TBARS, insulin levels, HOMA-
IR and HOMA-β indexes. Significant β-cell mass reduction was associated to an 
increased apoptotic rate and morphological/ultrastructural changes indicative of 
autophagic activity. All these changes were prevented by either sitagliptin or exendin-4. 
In cultured islets, F significantly enhanced insulin mRNA and GSIS, decreased Bcl-2 
mRNA levels and increased caspase-3 expression. Chloroquine reduced these changes 
suggesting autophagy participation in this process. Indeed, F induced the increase of 
both, VMP1 expression and LC3-II, suggesting that VMP1-related autophagy is 
activated in injured β-cell. Exendin-4 prevented islet-cell damage and autophagy 
development. Conclusions: VMP1-related autophagy is a reactive process against F-
induced islet dysfunction, being prevented by exendin-4 treatment. This knowledge 
could help to use autophagy as potential target for preventing progression from IGT to 
T2DM.   
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Short title:  
Incretins prevent VMP1-related autophagy induced by fructose rich diet  
 
Keywords: incretins, fructose-induced β-cell-injury, autophagy, β-cell mass, β-cell 
function.  
 
Abbreviations list:   
T2DM, Type 2 diabetes mellitus; ERS, endoplasmic reticulum stress; VMP1, Vacuole 
Membrane Protein 1; FRD, fructose-rich diet; IR, insulin resistance; DPP-IV, dipeptidyl 
peptidase-IV; LC3, microtubule-associated protein light chain 3; TBARS, thiobarbituric 
acid reactive substances; HOMA, homoeostasis model assessment; HOMA-β, HOMA 
for β-cell function; HOMA-IR, HOMA for insulin resistance; OGTT, oral glucose 
tolerance test; Vvi, volumen density; CQ, chloroquine. 
 
INTRODUCTION 
Type 2 diabetes (T2DM) is characterized by an early and progressive loss of pancreatic 
β-cell function and mass [1-3], being the latter associated to an increased rate of β-cell 
apoptosis [4]. This process has been ascribed to different causes, such as increased 
oxidative stress, mitochondrial dysfunction [5,6] and endoplasmic reticulum stress 
(ERS) response [7], but other factors could also play a pathogenic role. In this regard, 
autophagy could participate in the mechanism responsible for β-cell mass reduction in 
T2DM.  
Autophagy is a vacuolar, self-digesting mechanism that involves degradation of cellular 
components through activation of the lysosomal machinery [8]. Vacuole-Membrane 
Protein 1 (VMP1) is a trans-membrane protein whose expression triggers 
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autophagosome formation, remaining as an integrated part of it in mammalian cells. 
VMP1 interacts with Beclin1 through its hydrophilic C-terminal domain, which is 
necessary for early steps of autophagosome formation [9-11]. Streptozotocin induces 
the expression of VMP1 and autophagy in β-cells [12], while other alterations caused in 
these cells by high levels of free fatty acid and insulin resistance (IR) on ER function, 
can lead to ERS activating autophagy as a novel signaling pathway [13]. Similarly, in 
the Akita rodent model of diabetes, proinsulin gene mutation leads to protein misfolding 
and β-cell demise, that stimulate autophagy; its inhibition induces β-cell stress and 
apoptosis [14]. In this experimental model, since stimulation of autophagy occurs by 
inhibition of MTORC1, administration of rapamycin (MTORC1 inhibitor) to diabetic 
Akita mice, further stimulates autophagy, increasing autophagosome formation and 
enhancing autophagosome–lysosome fusion with the consequent improvement of 
diabetes and prevention of β-cell apoptosis [15]. On the other hand, Watada and Fujitani 
reported that during IR state where insulin secretion and β-cell mass are increased, 
autophagy activity is also enhanced to adapt to the dynamic changes occurring in β-cells 
[16]. Conversely, autophagy deficiency contributes to loss of β-cell mass in human 
T2DM [17]. At the clinical level, the reported links between inflammation, apoptosis 
and autophagy suggest that modulation of the autophagic processes would protect β-
cells from cytotoxicity induced by inflammatory mediators [18]. This growing evidence 
suggests the possibility of exploring autophagic processes to develop treatment tools for 
protection of β-cell in T2DM. 
On the other hand, administration of a fructose-rich diet (FRD) to normal adult rats 
induces multiple metabolic disturbances, IR and impaired glucose tolerance (IGT) or 
diabetes, depending on the treatment duration [19]. These changes are accompanied by 
a significant β-cell mass decrease, apparently related to an increase in their apoptosis 
  5
rate [20]. In this context, both β-cell function and mass, are strongly influenced by 
incretins [21-22] and their effects are significantly decreased in T2DM [23,24]. Since 
incretins are rapidly degraded by dipeptidyl peptidase-IV (DPP-IV), two different 
approaches have been used to overcome this problem: the use of exendin-4, a potent 
GLP-1 receptor agonist resistant to enzymatic degradation [25,26], and the 
administration of different DPP-IV inhibitors [27]. We have previously shown that the 
co-administration of either exendin-4 or a DPP-IV inhibitor (sitagliptin) with a FRD 
decreased β-cell apoptosis rate and prevented the development of all the FRD-induced 
functional abnormalities [28]. However, there are no evidences on the possible role of 
autophagy in the fructose-induced injury on β-cell mass and function. 
In an attempt to elucidate this issue, we have used a double experimental approach: an 
in vivo model (normal rats fed with a FRD), that resembles all the clinical/metabolic 
characteristics of people at high risk for T2DM and an in vitro model (cultured islets 
isolated from untreated normal rats). In both cases we have tested: a) the role of 
autophagy and incretins on fructose-induced alteration in β-cell mass and function b) if 
incretin effect depends on its general metabolic impact or it is a direct effect of exendin-
4 on islets. 
 
MATERIALS AND METHODS 
Chemicals and drugs: Collagenase was obtained from Serva Feinbiochemica 
(Heidelberg, Germany); BSA (bovine serum albumin) fraction V, rabbit anti-caspase-3 
antibody, mouse monoclonal anti β-actin antibody and other reagents were from Sigma-
Aldrich. Anti-Bcl-2 (rabbit polyclonal, sc-492), and anti- microtubule-associated protein 
light chain 3 (LC3; goat polyclonal, sc 16755) antibodies were from Santa Cruz 
Biotechnology Inc. (Santa Cruz, CA, USA). Polyclonal rabbit antiserum to VMP1 was 
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developed by Vaccaro’s laboratory [9]. Alexa Fluor 488 and 594 antibodies (Molecular 
Probes) were used for immunofluorescence assays. Peroxidase-labeled anti-rabbit and 
anti-goat IgG antibodies were used for Western blot according to GE Healthcare. 
Exendin-4 was obtained from Bachem California Inc. (Torrance, CA, USA) while 
sitagliptin was kindly provided by Process Research, Merck Research Laboratories.  
In vivo Model 
Experimental groups: Normal adult male Wistar rats (180-200 g body weight) were 
divided into two groups: a control group fed with a standard commercial diet (C) and 
other group that received the same diet plus 10% fructose (wt/vol) in the drinking water 
(F) for 3 weeks. Animals from both groups were randomly divided into three subgroups 
(n 20 in each experimental group): untreated (C and F), treated with either sitagliptin 
(CS and FS) or with exendin-4 (CE and FE). Altogether we employed 120 rats. All the 
animals were maintained in a room with controlled temperature (25° C) and lighting 
periods (12 h light/dark cycle). CE and FE rats were injected twice a day with exendin-4 
(0.35 nmol/kg body weight/ip), while sitagliptin was administered orally (57.6 mg/100 
g body weight/day) premixed with the milled pellet at 0.6% (wt/wt). Water and food 
intake were measured daily, while individual body weight was recorded once a week. 
Animal experiments and handling were performed according to the “Ethical principles 
and guidelines for experimental animals” of the Swiss Academy of Medical Sciences 
(3rd Edition 2005, mail@samw.ch). 
 
Plasma measurements: At the end of dietary period, blood samples from non-fasted 
animals were collected from the retro-orbital plexus under light halothane anesthesia at 
9:00 am to measure plasma glucose, triacylglycerol, lipid peroxidation (thiobarbituric 
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acid reactive substances [TBARS]) and insulin concentration. Glucose was measured 
with test strips (Accu-Chek Performa Nano System, Roche Diagnostics. Mannheim, 
Germany) and the triacylglycerol levels were determined using commercial kits 
(BioSystems S.A., Buenos Aires, Argentina), implemented in an automated clinical 
analyzer. TBARS were determined by a fluorimetric assay and results were expressed 
as pmol of malondialdehyde (MDA) per mg of plasma protein, measured with the Bio-
Rad Protein Assay kit (Bio-Rad Lab, RC, USA). Plasma insulin was measured by 
radioimmunoassay (RIA) using a specific antibody against rat insulin (Sigma-Aldrich 
Co.), purified rat insulin standard (Novo Nordisk Pharma Argentina) and highly purified 
porcine insulin labeled with 125I. Insulin resistance was determined with the homeostasis 
model assessment-IR (HOMA-IR), using the formula: [insulin (μU/L) x glucose 
(mmol/L)]/22.5; β-cell function was quantified with the HOMA-β using the formula: 
[insulin (μU/L) x 20/glucose (mmol/L)] – 3.5 [29]. Since these indexes were validated 
in humans but not in rodents, we compared the values measured in C with the other 
experimental groups instead of using a cut-off threshold value. 
 
Oral glucose tolerance test (OGTT): OGTT was performed in six 12-h fasted rats 
from each experimental group. Glucose (1 g/kg of body weight in saline solution), was 
given through a gavage tube placed into the stomach. Blood samples were obtained 
from the retro-orbital plexus under light ketamin and midazolam anesthesia (80 mg/kg 
and 5 mg/kg of body weight, respectively), at 0, 30, 60 and 120 min following the 
glucose load. In these samples, glucose concentration was measured with test strips 
(Accu-Chek Performa Nano System, Roche Diagnostics. Manheim, Germany). Results 
were expressed as the area under the glucose curve (AUC) in mmol/L/min.  
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Immunohistochemical studies: The whole pancreas from three animals of each 
experimental group was carefully dissected and removed and its wet weight was 
recorded. Thereafter, a piece of the tail of each pancreas was obtained, fixed in 10% 
formaldehyde and embedded in paraffin. Serial sections of each one of the fixed 
pancreases (5 µm) were obtained from three different depths of the blocks with a 
rotatory microtome and mounted on silanized slides (3-amino-propyltriethoxy-silane; 
Sigma-Aldrich). Sections were deparaffinized, incubated for 30 min in 3% hydrogen 
peroxide in methanol to block the endogenous peroxidase activity and rehydrated in a 
descending ethanol series, followed by incubation in 2.5% porcine serum to reduce non-
specific binding. The slides were then incubated for 24 h at 4 C in a humidified 
chamber with our own anti-guinea pig insulin antibody (1:20,000). The final staining 
was performed by incubating the slides during 30 min with appropriately diluted 
streptavidin-biotin complex (1:40 and 1:20, respectively; Sigma-Aldrich); thereafter, the 
sections were stained with hematoxylin.  
 
Morphometric analysis: Morphometric analysis was performed by videomicroscopy 
using a Jenamed 2 Carl Zeiss light microscope and a RGB CCD Sony camera, together 
with the OPTIMAS software (Bioscan Incorporated, Edmons, WA, USA). We 
measured the following parameters: total pancreatic area (excluding connective tissue) 
and islet -cell area (Volumen density, Vvi). To estimate islet -cell mass, we 
multiplied the respective Vvi by the weight of the total pancreas [30].   
 
β-cell apoptosis: The propidium iodide technique was used to identify apoptotic bodies 
[31]. For this purpose, deparaffinized-rehydrated pancreas sections were incubated for 
30 min in a dark humidified chamber with a propidium iodide (4 µg/mL; Sigma-
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Aldrich) and ribonuclease A (100 µg/mL; Sigma-Aldrich) solution. Then, the sections 
pretreated with guinea pig non-immune sera diluted in Tris-buffered saline (pH 7.4) 
were incubated for 1 h with the insulin antibody. To measure the fluorescence labeling 
of the primary antibody, the slides were incubated at room temperature for 45 min in the 
dark chamber with the IgG-specific, fluorescein-conjugated, affinity-purified guinea pig 
antibody (against heavy and light IgG chains; Santa Cruz Biotechnology Inc., CA, 
USA). The sections were then washed with PBS and mounted in Tris–glycerol (pH 8.4) 
for analysis with an immunofluorescent Zeiss Axiolab epifluorescence microscope 
equipped with an HBO50 mercury lamp and two different filters. For the quantitative 
assessment of apoptosis, positively immunofluorescence-labeled β-cells were counted 
under a 40 objective lens in sections obtained from different levels of the paraffin 
blocks. The number of apoptotic β-cells was expressed as the percentage of the total 
number of β-cells counted.  
 
Transmission Electron Microscopy: Pancreas sections from four animals of each 
experimental group were processed for transmission electron microscopy by standard 
procedures. Grids were examined under a Carl Zeiss C-10 electron microscope 
(Laboratorio Nacional de Investigación y Servicios en Microscopía Electrónica, 
University of Buenos Aires) and β-cell integrity (i.e. ER stress as evidenced by 
dilatation of the membranous structures) and the presence/abscence of granules 
containing insulin were evaluated.  
 
Vacuolization: Cell-vacuolization was analyzed in samples preparation for electron 
microscopic studies. Tissue samples were fixed in 1% glutaraldehyde in 0.1 M 
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phosphate buffer and stained with 1% toluidine blue in borax buffer for quantification. 
Results were expressed as vacuoles per cells/ mm2 related to control (% of control). 
 
Immunofluorescence studies: Serial sections of three pancreases from each group 
were immunostained using Alexa fluorocromes (Molecular Probes) indirect labeling 
technique. Deparaffinized-rehydrated pancreas sections were thereafter incubated in 
Sodium Citrate Buffer (10 mM Sodium Citrate, 0.05% Tween 20, pH 6.0) at 95º C, 
washed several times, further incubated with blocking solution for 1 h at room 
temperature and finally incubated with primary antibodies (polyclonal rabbit antiserum 
to VMP1 (1:100 dilution) and polyclonal goat anti-insulin from Santa Cruz Biotech 
(1:500 dilution) overnight at 4º C. Antibodies were used according to the 
manufacturer’s instructions. Thereafter, they were washed several times and incubated 
with secondary antibodies (donkey anti-rabbit Alexa Fluor 594 and donkey anti-goat 
Alexa Fluor 488 (Molecular Probes) for immunostaining. Samples were mounted in 
DABCO (Sigma-Aldrich) and observed in Fluorescent microscopy. 
 
Islet isolation and insulin secretion measurement: The pancreas from six animals of 
each experimental group was removed and islets were isolated by collagenase digestion 
[32]. Groups of 5 islets from each experimental group were incubated for 60 min at 37° 
C in 0.6 mL of Krebs-Ringer Bicarbonate buffer (KRB), pH 7.4, previously gassed with 
CO2/O2 (5%/95%), containing 1% (w/v) BSA and 3.3, 8.3 and 16.7 mM glucose [33]. 
At the end of the incubation period, aliquots from the medium were taken to measure 
insulin by RIA as described above.  
 
In vitro Model 
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Islet culture: Freshly isolated islets from 18 untreated normal rats were cultured in 
RPMI-1640 medium (Microvet SRL, Argentina), pH 7.4 containing 2 g/L NaHCO3, 5% 
(v/v) fetal bovine serum, 1% penicillin/streptomycin, and 10 mM glucose at 37° C in a 
humid atmosphere (5% CO2/95% O2). Islets were cultured for 3 days in the absence 
(control C) or the presence of 2 mM fructose (F) and the combination of fructose with 5 
nM exendin-4 (FE) or 10 µM chloroquine (FCQ; an inhibitor of autophagic flux). 
Medium was renewed every other day. After culture period, islets were preincubated in 
KRB buffer, pH 7.4, previously gassed with a mixture of CO2/O2 (5/95%), containing 
1% (w/v) BSA and 3.3 mM glucose at 37° C for 45 min. After this preincubation 
period, islets where further incubated with different glucose concentration to measure 
glucose- stimulated insulin secretion as described above in the in vivo model. 
 
Quantitative Real-Time PCR: Total RNA was isolated from islets obtained from each 
experimental culture condition using Rneasy mini kit (Qiagen). The RNA integrity was 
checked by agarose-formaldehyde gel electrophoresis. Possible contamination with 
protein or phenol was controlled by measuring the 260:280 nm absorbance ratio, 
whereas DNA contamination was avoided by treating the sample with DNase I 
(Invitrogen); 1 μg of total RNA was used for reverse transcription with SuperScript III 
Reverse Transcriptase (Invitrogen) and oligo-dT. Real-time PCRs were run in triplicate 
using FastStart SYBR Green Master (Roche) in the iCycler 5 (Bio-Rad). The cycling 
profile used was: 1 cycle of 1 min at 95° C (DNA denaturation), 40 cycles of 30 sec at 
95° C, 30 sec at 60° C and 30 sec at 72° C followed by a melting curve from 55° C to 
90° C. Quantified values were normalized against the housekeeping gene β-actin, using 
the individual efficiency calculated with a standard curve for each gene.  
Specific pairs of primers based on rat cDNA sequences were designed as follows:  
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Bcl-2 (L14680.1) forward primer 5´-CGGGAGAACAGGGTATGA-3´, reverse primer 
5´-CAGGCTGGAAGGAGAAGAT-3´; Caspasa-3 (NM_012922.2) forward primer 5´-
CAAGTCGATGGACTCTGGAA-3´, reverse primer 5´- 
GTACCATTGCGAGCTGACAT-3´; VMP1 forward primer 5’-
GGTGCTGAACCAGATGATGA-3’, reverse primer 5’-
GCACCAAAGAAGGTCCAAA-3’; Insulin (PO1323-1) forward primer 5´-
TGTGGTTCTCACTTGGTGGA-3´, reverse primer 5´-
CAGTGCCAAGGTCTGAAGGT-3´; β-actin (NM_031144.3) forward primer, 5′-
AGAGGGAAATCGTGCGTGAC-3′; reverse primer, 5′-
CGATAGTGATGACCTGACCGT-3′. 
 
Western Blotting: Islets were homogenized in 80 mM Tris (pH 6.8), 5 mM EDTA, 5% 
SDS, 5% dithiothreitol, 10% glycerol and protease inhibitors (1 mM phenyl-
methylsulfonyl-fluoride and 4 mg aprotinin). Samples were fractionated under reducing 
conditions by SDS/PAGE and electroblotted to polyvinylidene difluoride transfer 
membrane (Amersham Hybond-P, GE Healthcare, UK). The amount of protein loaded 
onto the gel was quantified using the Bio-Rad Protein Assay kit (Bio-Rad Lab, RC, 
USA). Nonspecific binding sites were blocked with non-fat milk solution at 4º C for 90 
min for caspase-3, Bcl-2, VMP1 and LC3 and overnight for β-actin. The membranes 
were then incubated with specific antibodies against Bcl-2 (1:2,000 dilution), caspase-3 
(1:1,000 dilution), VMP1 (1:100 dilution) and LC3 (1:200 dilution) at 4° C overnight, 
or for 90 min with antibody against β-actin (1:10,000 dilution). After rising with T-
TBS, the blots were incubated with anti-rabbit IgG-HRP for 1 h at room temperature. 
For β-actin, the horseradish-peroxidase-conjugated anti-mouse IgG-HRP was used as 
secondary antibody. Proteins were revealed by using and enhanced chemiluminescence 
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detection system (ECL Prime, Amersham, GE Healthcare, UK). Finally, the bands were 
quantified using the Image Studio Digits Version 3.1 software.  
 
Statistical analysis: The experimental data were statistically analyzed using Variance 
Analysis (One way ANOVA) and "post hoc" Bonferroni and Tamhane tests for multiple 
comparisons. Results are expressed as mean ± SEM. Differences were considered 
significant when P < 0.05. 
 
RESULTS 
In vivo model 
Body weight, and caloric intake: A comparable caloric intake was recorded in C and F 
rats (64.7 ± 4.3 vs. 73.9 ± 3.7 Kcal/rat/day, respectively), but with different nutrient 
percentage distribution (carbohydrates:proteins:lipids: 45:43:12 vs. 63:28:8, 
respectively). Neither exendin-4 nor sitagliptin affected these caloric intake (CE: 63.8 ± 
2.3; CS: 62.4 ± 2.5; FE: 77.2 ± 8.1; FS: 69.3 ± 4.5 Kcal/rat/day). Accordingly, no 
significant differences were recorded in body weight values among the experimental 
groups, except that the administration of exendin-4, but not sitagliptin, significantly 
reduced body weight gain in C rats (body weight gain during 3 weeks: C: 88 ± 8; CE: 
63 ± 4*; CS: 82 ± 6; F: 74 ± 7; FE: 65 ± 6; FS: 89 ± 5 g; *p<0.05 vs. C). 
 
Plasma measurements, HOMA indexes and OGTT: While plasma glucose values 
were similar in all experimental groups, triglyceride, TBARS and insulin levels as well 
as HOMA-IR and HOMA-β indexes were significantly higher in F rats than in C ones 
(p<0.05; Table 1). These data indicate that F rats have developed dyslipidemia, IR and 
an increased oxidative stress rate. Both exendin-4 and sitagliptin prevented all these 
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abnormalities when they were co-administered to F rats (p<0.05 vs. F) but did not 
produce any effect in C animals. The area under the glucose curve (AUC) during the 
OGTT was significantly higher in F than in C rats (Table 1). That means that high 
insulin levels in these rats were sufficient to maintain basal serum glucose levels within 
normal range, but not to cope with the larger demand induced by the glucose load. Once 
again, these high AUC values returned to almost control levels in F rats by co-
administration of either exendin-4 or sitagliptin.              
 
Insulin secretion: Islets isolated from animals of all experimental groups increased the 
glucose-stimulated insulin secretion (GSIS) as a function of the glucose concentration in 
the incubation media (Figure 1). While no differences were recorded among the 
experimental groups studied at basal glucose concentration, islets from F rats released 
significantly larger amounts of insulin than C ones in response to 8.3 and 16.7 mM 
glucose. These higher values decreased significantly to almost control ones when F rats 
were co-treated with exendin-4 or sitagliptin.  
 
Morphometric analysis: The morphometric analysis from C, F, FE and FS rats 
demonstrated that islet β-cell mass was significantly decreased in F rats (Figure 2A). 
Co-treatment with exendin-4 or sitagliptin prevented such reduction, thus islet β-cell 
mass attained values close to those recorded in control animals. While the effect of 
exendin-4 was significantly larger than the one of sitagliptin, none of these drugs 
significantly affected this parameter in C animals.  
β-cell apoptosis: the percentage of β-cell apoptotic rate was higher in F compared to C 
rats (Figure 2B). Such increased apoptotic rate was prevented by co-administration of 
exendin-4 or sitagliptin, thus attaining values close to those measured in control rats.  
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Electron Microscopy. Vacuolization: Thin slides stained with toluidine blue and 
electron microscopy images of pancreas obtained from all experimental groups, 
revealed that islet morphology is consistent with biochemical results (Figure 3 and 4). 
Light-microscopic examination of such sections showed that central islet-cells from F 
animals presented a great number of cytoplasmatic vacuoles (Figure 3A). Quantification 
confirms that F animals presented more than 400% vacuoles per cell/mm2 than those 
from C animals (expressed as percentage of control; p<0.05; Figure 3B). Exendin-4 or 
sitagliptin coadministration significantly reduced such cell-vacuolization (FE and FS vs. 
F rats p<0.05).  
β-cell ultrastructure is shown in Figure 4;  β-cells of C, CS and CE animals, (Figure 4 
A, C and E, X7,000) presented a normal appearance (i.e.; normal nuclear size, 
chromatin disposition and insulin granules); conversely, β-cells of animals treated with 
fructose showed chromatin aggregation and reduced nucleus size, less number of 
secretory granules, higher degree of cell-vacuolization and larger size of endoplasmic 
reticulum (Figure 4B, B1 and B2; X7,000; X20,000 and X50,000 respectively). These 
deleterious effects on cell ultrastructure were prevented by co-administration of either 
sitagliptin or exendin-4 (Figure 4D, D1, D2 and 4F, F1, F2, respectively).  
Furthermore, fructose-induced autophagy was evidenced by the presence of 
autophagosomes (double-membrane structures containing cytoplasmic material) and 
autolysosomes (single-membrane structures containing cytoplasmic constituents at 
different stages of degradation) (Figure 4B, B1 and B2). Animals co-treated with 
sitagliptin still presented autophagic features (Figure 4D, D1 and D2) while exendin-4 
fully prevented fructose-induced autophagy (Figure 4F, F1 and F2). This data suggest 
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that sitagliptin exerts an uneven preventive effect on β-cell dysfuntion (see above 
results) and autophagy.  
 
Immunofluorescence studies: Pancreas tissue sections from all experimental groups 
were immunostained with specific VMP1 and insulin antibodies. A remarkable β-cell 
co-distribution of VMP1 and insulin was depicted in F animals (Figure 5A), suggesting 
the presence of VMP1-related autophagy in these cells. Fructose-induced VMP1 
expression in β-cells was prevented by co-administration of exendin-4 but not by 
sitagliptin, which enhanced VMP1 expression in β-cells (Figure 5B and C), as shown by 
the presence of autophagic features recorded in FS animals (electron microscopy, Figure 
4).  
Once again sitagliptin was less effective than exendin-4 to prevent the development of 
fructose-induced autophagy in β cells.   
In vitro model 
Insulin secretion and mRNA levels: the presence of fructose in the culture medium (F 
islets) increased significantly insulin mRNA levels (Figure 6A). This effect was not 
longer observed when islets were cultured with the combination of fructose with 
exendin-4 (FE islets; Figure 6A). Inhibition of autophagic flux by the addition of 
chloroquine to the culture medium (FCQ islets) significantly reduced insulin mRNA to 
control levels.  
Insulin was released in response to glucose in a dose-dependent manner in all the 
culture conditions tested (Figure 6B). While, islets treated with fructose did not release 
more insulin than control group at basal glucose concentration (3.3 mM), such release 
was significantly enhanced in response to 16.7 mM glucose.  
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Islets cultured with fructose plus exendin-4 (FE islets) released significantly larger 
amounts of insulin at both glucose concentrations tested (Figure 6B). However, when 
autophagy was inhibited (FCQ condition), the enhancing effect of fructose on glucose-
induced insulin secretion in response to 16.7 mM  glucose, was not any longer observed 
(Figure 6B). Altogether, these data suggest a critical role of autophagy in the direct 
effect of fructose on β-cell secretoy function.  
 
mRNA and protein levels of apoptotic/antiapoptotic markers: The presence of 
fructose in the culture medium significantly decreased Bcl-2 mRNA levels. Addition of 
either exendin-4 or chloroquine to the medium (Figure 7A), blocked this effect. 
However, such changes were not reflected in Bcl-2 protein concentration in none of the 
culture conditions tested (Figure 7B).  
Fructose significantly enhanced caspase-3 mRNA levels; effect that was prevented by 
simultaneous addition of exendin-4 to the medium. Autophagic flux inhibition however, 
did not prevent fructose effect on caspase-3 mRNA levels (Figure 7C).  
Fructose significantly increased the amount of caspase-3 (124%) compared to C islets 
(Figure 7D). Addition of exendin-4 to the fructose culture medium prevented such 
increase, attaining values close to those measured in C islets. Chloroquine addition 
(FCQ islets) also significantly decreased caspase-3 protein level, thus suggesting that 
autophagy is involved in the fructose-induced β-cell apoptosis process.  
 
mRNA and protein levels of autophagic related proteins: VMP1 mRNA levels were 
significantly increased in islets cultured with fructose, and its high expression was 
prevented by addition of either exendin-4 or chloroquine to the culture medium (FE and 
FCQ islets, respectively) (Figure 8A). Similarly, fructose significantly increased VMP1 
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protein levels and such increase was prevented by addition of exendin-4 to the culture 
medium. Since chloroquine inhibits autophagy flux (formation of autolysosomes) with 
autophagosomes accumulation, as expect, its addition to the culture medium did not 
decrease VMP1 protein concentration (Figure 8B).  
Islets cultured with fructose underwent a significant increase in LC3II level compared to 
C islets, while addition of exendin-4 to the culture medium prevented this effect. 
Consistent with VMP1 protein level, LC3II was higher in the presence of chloroquine in 
the medium (Figure 8C). Accordingly, fructose induced the enhancement of 
LC3II/LC3I ratio (C: 1 ± 0.11; F: 1.59 ± 0.12; p<0.05 vs. C). Addition of exendin-4 
prevented this increase (FE: 1.2 ± 0.10; p<0.05 vs. F), while LC3II/LC3I ratio was 
higher in the presence of chloroquine (FCQ: 2.53 ± 0.22; p<0.05 vs. F). Altogether, 
these changes suggest that fructose induces VMP1-related autophagy in β-cells that is 
effectively prevented by exendin-4.  
 
DISCUSSION 
Normal rats fed with a FRD developed a significant increase in serum triglyceride 
levels, an IR state (hyperinsulinemia with normoglycemia and increased HOMA-IR and 
HOMA-β indexes) and their islets showed an enhanced release of insulin in vitro in 
response to high glucose. These changes were associated with an increased oxidative 
stress (high serum TBARS levels), IGT and a significant decrease in β-cell mass, 
mainly ascribed to an increased apoptosis rate [20,28,34,35]. This later effect would be 
ascribed to the combination of ERS [7], oxidative stress, mitochondrial dysfunction, and 
glucolipotoxicity [5,6] present in these rats. The high release of fatty acids with high 
saturated/unsaturated ratio by adipose tissue of F rats (either in vivo or in vitro) would 
directly stimulate β-cell apoptosis [34]. Co-administration of either exendin-4 or 
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sitagliptin prevented the development of all these changes as it was previously reported 
[28].  
Currently, we have shown that these metabolic, endocrine and morphological 
abnormalities observed in F rats, were associated with morphological indicators of 
autophagy: a significant increase of β-cell-vacuolization, presence of double-membrane 
structures containing cytoplasmic material (autophagosomes) and single-membrane 
structures containing cytoplasmic constituents at different stages of degradation 
(autolysosomes). They also showed β-cell chromatin aggregation, reduced nucleus size, 
less number of secretory granules and larger size of endoplasmic reticulum. All these 
autophagy markers could be induced by different abnormalities recorded in these 
animals such as IR, oxidative stress and ERS [36].  
Co-administration of exendin-4 or sitagliptin to F rats improved the ultrastructural 
features of the pancreas: β-cells of FS and FE rats showed a higher number of insulin 
granules and a marked reduction of the endoplasmic reticulum dilatation than F rats, 
suggesting that these compounds prevent the development of ERS and protect β-cell 
against apoptosis. Beneficial effect of DPP-IV inhibitors and GLP-1 receptor agonists 
on β-cell mass and function has been consistently reported in different models of T2DM 
[37-40] as well as in our prediabetes model [28]. Further, the autophagic related-protein 
(VMP1) was not longer expressed when those abnormalities were prevented by 
exendin-4 co-administration suggesting that autophagy is activated as a β-cell response 
to fructose-induced β-cell injury. We cannot discard however, a direct effect of exendin-
4 upon autophagic activity. In fact, the presence of autophagosomes and autolysosomes 
were only prevented by exendine-4 co-treatment. Since sitagliptin is a DPP-IV inhibitor, 
the potential increase of circulating active GLP-1 levels would be lower (within 
physiological range) than those reached after exendin-4 administration 
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(pharmacological levels) and not sufficient to prevent fructose-induced autophagic 
process. 
The simultaneous protective effect of exendin-4 upon the development of fructose-
induced β-cell injury and enhanced autophagy observed in our study is supported by 
several previous reports, namely: a) exendin-4 improves β-cell function in autophagy-
deficient β-cell [41], b) liraglutide, another GLP-1 analogue, induced autophagy and 
exerted protective effects on pancreatic β-cells in vitro and in vivo [42] and c) DPP-IV 
inhibitors restored β-cell function through activation of autophagy in high fat diet-
induced obese mice [43]. 
Attempting to elucidate the mechanism by which exendin-4 exerts its effect on β-cell 
autophagy, we have cultured isolated rat islets in presence of fructose alone or together 
with exendin-4 or chloroquine. Fructose can be transported in β cells by the GLUT2 
glucose transporter –though with lower efficiency- as well as by the taste receptors 
T1R2 and T1R3, present in these cells [44]. Accordingly, fructose significantly 
enhanced the glucose-induced release of insulin.  
While exendin-4 enhanced the secretion of insulin at basal glucose concentration, it did 
not significantly modify fructose effect at a stimulatory glucose concentration. In the 
later condition, probably the known enhancing effect of exendin-4 on glucose-induced 
insulin secretion masked its potential preventive effect on the higher release of insulin 
associated to fructose treatment. Conversely, addition of an autophagic flux inhibitor 
(CQ) to the cultured medium blocked the fructose effect on insulin release at 16.7 mM 
glucose. Anyhow, either exendin-4 or chloroquine have blunted the fructose-induced 
effect on insulin mRNA levels, suggesting a critical role of autophagy in the direct 
effect of fructose on β-cell function.   
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Simultaneously, fructose decreased mRNA levels of Bcl-2 and enhanced those of 
caspase-3, effects that were prevented by addition of either exendin-4 or chloroquine to 
the culture medium; the data indicate that autophagy would be also involved in the 
fructose-induced β-cell apoptosis.  
Increased VMP1 mRNA and protein levels and LC3-II were also found in fructose-
cultured islets, suggesting the induction of VMP1-related autophagy by fructose. VMP1 
is not constitutively expressed in the pancreas but it is highly activated in β-cells in 
response to experimental diabetes and could participate in the molecular pathways by 
which β cell triggers autophagy [12,45].  
On the other hand, during autophagy, Pro-LC3 is cleaved to LC3-I, which is lipidated to 
LC3-II and subsequently recruited to the mature autophagosome [46], reason why LC3-
II is considered a useful biomarker of autophagy. Accordingly, both LC3 and VMP1 
were significantly increased in F islets, suggesting that VMP1-related autophagy is 
activated in β cells by fructose-induced cell damage as a protective response. Further, 
Barlow and colleagues showed that autophagy plays an important role in regulating 
normal function of pancreatic β-cells and insulin-target tissues, including skeletal 
muscle, liver, and adipose tissue, suggesting that autophagy would represent a 
protective mechanism against oxidative stress [47]. Autophagy/lysosomal degradation 
also defends β-cells against proteotoxicity induced by human islet amyloid polypeptide 
[48].    
Our data obtained under in vitro conditions are not strong enough to demonstrate 
whether the effect of exendin is due to a direct action on the islets rather than a 
consequence of its effect on overall metabolic homeostasis. However, this work 
strongly showed that: a) fructose, either in an in vivo or in vitro model, enhances GSIS 
and β-cell apoptotic rate; b) in the in vivo model, fructose simultaneously increased 
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glycoxidative stress (increased TBARs), lipotoxicity (high plasma triglyceride levels) 
and insulin demand (IR); altogether these impaired conditions would induce all those β-
cell alterations; c) in both models fructose induced-impairments were associated with 
VMP1-related autophagy and d) either exendin-4 or sitagliptin co-administrated with 
fructose and the addition of exendin-4 to the culture medium, prevent the development 
of many fructose-induced islet injury. On account of these results we postulate that, in 
our experimental conditions, VMP1-related autophagy is a reactive process that 
attempts to protect/compensate fructose-induced islet dysfunction and β-cell apoptosis. 
The fact that in vivo conditions sitagliptin exerts its preventive effect even when 
autophagy markers were still present supports our assumption. Additionally, in a recent 
review Lee concludes that autophagy may improve the ability of diverse metabolic 
organs, including β cells, to handle metabolic stress [49].  
Altogether, the evidences provided could help to design effective strategies using 
autophagy as potential target for preventing disease progression from IGT to T2DM.  
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TABLES AND FIGURES 
Table 1. Serum levels of different metabolic and endocrine parameters. 
AUC: Area under the glucose curve measured in six animals from each group as 
mmol/L/min. during OGTT. Values represent means ± SEM of serum concentration of 
glucose (mg/dL), triglyceride (mg/dL), insulin (ng/mL) and TBARS (pmol/mg prot); (n 
20 in each group) *p<0.05 vs. C; #p<0.05 vs. F. 
 
Figure 1. Glucose-induced insulin secretion in vitro 
Glucose-induced insulin secretion in response to 3.3, 8.3 and 16.7 mmol/L glucose by 
islets isolated from all experimental groups (n 6 animals per group). Insulin released 
into the incubation media was expressed in ng of insulin per islet/1 h; each bar 
represents means ± SEM of six independent experiments. *p<0.05 vs. C; #p<0.05 vs. F 
 
Figure 2. Pancreas morphometric analysis 
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A. Morphometric analysis of islet β-cell mass (mg) measured in all experimental 
groups. For its estimation, we multiplied the respective Vvi by the weight of the total 
pancreas. Bars represent means ± SEM of 4 cases from three different levels of the 
block corresponding to three animals from each group. *p<0.05 vs. C; #p<0.05 vs. F. B. 
Morphometric analysis of β-cell apoptotic rate measured in each experimental group; 
bars represent means ± SEM of 4 cases from three different levels of the block 
corresponding to three animals from each group; % of β-cell apoptotic rate highly 
increased in F compared to C. After exendin-4 and sitagliptin administration, the pattern 
is comparable to that recorded in C rats. *p<0.05 vs. C; #p<0.05 vs. F 
 
Figure 3. Islet vacuolization 
A. Representative thin sections of the pancreas stained with toluidine blue from C, F, 
FE and FS rats. Inset: at larger magnitude, the picture shows a cell with great number of 
vacuoles. B. Quantification of cell vacuoles measured in all experimental groups. 
Results are expressed as vacuoles per cell/mm2 related to control (% of control). Bars 
represent means ± SEM of 3 cases corresponding to four animals from each group; *p 
<0.05 vs. C; #p <0.05 vs. F. 
 
Figure 4. β-cell ultrastucture 
Electron microscopy images of the pancreas obtained from animals from all 
experimental groups: C (A), F (B, B1, B2; X7,000, X20,000 and X50,000 respectively), 
CS (C), FS (D, D1, D2; X7,000, X20,000 and X50,000 respectively), CE (E) and FE (F, 
F1, F2; X7,000, X20,000 and X50,000 respectively) rats. Details of autophagic 
structures (autophagosome and autolysosomes pointed with black arrows) are shown in 
B2 and D2 (X50,000) and of reticulum stress features (pointed with black triangles) in 
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B1 and D1 (X20,000). Scale bars: Figure A – D: 1 m; Figure B1, D1 and F1: 0.5 m; 
Figure B2, D2 and F2: 200 nm. Images are representative of those obtained from 4 
animals from each experimental group. 
 
Figure 5. VMP1 and insulin immunofluorescence 
VMP1 (red) and insulin (green) immunofluorescence. Pancreas tissue of three animals 
from each experimental group treated as described in Materials and Methods section. A. 
Tissue sections of animals from control or fructose group. B. Tissue sections of animals 
from control or fructose group plus sitagliptin. C. Tissue sections of animals from 
control or fructose group plus exendin-4. Details of VMP1-positive aggregates in β-
cells (see Merge images) indicate β-cell VMP1-related autophagy. Magnification X400 
 
Figure 6. Insulin release and mRNA levels 
A. Insulin mRNA relative expression (real time PCR) in islets previously cultured in the 
absence (control C islets) or the presence of 2 mM fructose (F islets) and the 
combination of fructose with 5 nM exendin-4 (FE islets) or 10 µM chloroquine (FCQ 
islets). β-actin was used as internal standard; values are expressed in arbitrary units 
(AU) with respect to mRNA level determined in C islets. Bars represent mean values ± 
SEM from three independent experiments. *p<0.05 vs. C; #p<0.05 vs. F. B. Glucose-
induced insulin secretion in response to 3.3 and 16.7 mmol/L glucose by islets cultured 
under the different conditions tested. Insulin released into the incubation media was 
expressed as ng of insulin per islet/1 h. Bars represent mean values ± SEM from five 
independent experiments. n 18 rats;  *p<0.05 vs. C; #p<0.05 vs. F. 
 
Figure 7. Bcl-2 and caspase-3 gene expression 
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A and C. Bcl-2 (A) and caspase-3 (C) mRNA relative expression (real time PCR) in 
islets previously cultured in the absence (control C islets) or the presence of 2 mM 
fructose (F islets) and the combination of fructose with 5 nM exendin-4 (FE islets) or 10 
µM chloroquine (FCQ islets). β-actin was used as internal standard; values are 
expressed in arbitrary units (AU) with respect to mRNA level determined in C islets. 
Bars represent mean values ± SEM from three independent experiments. n 18 rats;   
*p<0.05 vs. C; #p<0.05 vs. F. B and D. Bcl-2 (B) and caspase-3 (D) protein 
concentration determined by Western Blot in islet homogenates obtained from each 
experimental culture condition using β-actin as housekeeping protein. A representative 
blot from three independent experiments is shown in each case. Bars below the blot 
represent mean values ± SEM expressed in arbitrary units (AU) as the ratio between the 
protein of interest and β-actin band intensity. n 18 rats;  *p<0.05 vs. C islets; #p<0.05 
vs. F islets.  
 
Figure 8. VMP1 and LC3 gene expression 
A. VMP1 mRNA relative expression (real time PCR) in islets previously cultured in the 
absence (control C islets) or the presence of 2 mM fructose (F islets) and the 
combination of fructose with 5 nM exendin-4 (FE islets) or 10 µM chloroquine (FCQ 
islets). β-actin was used as internal standard; values are expressed in arbitrary units 
(AU) with respect to β-actin mRNA level determined in each group. Bars represent 
mean values ± SEM from three independent experiments. n 18 rats;  *p<0.05 vs. C; 
#p<0.05 vs. F. B. VMP1 protein level determined by Western Blot in islet homogenates 
obtained from each experimental culture condition tested using β-actin as housekeeping 
protein. A representative blot from three independent experiments is shown. Bars below 
the blot represent mean values ± SEM expressed in arbitrary units as the ratio between 
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the protein of interest and β-actin band intensity relative to C group. *p<0.05 vs. C 
islets; #p<0.05 vs. F islets. C. LC3 protein level determined by Western Blot in islet 
homogenates from every culture condition. A representative blot from three 
independent experiments is shown. Bars below the blot represent mean values ± SEM 
expressed in arbitrary units as the ratio between protein of interest and β-actin band 
intensity relative to C group. n 18 rats;  *p<0.05 vs. C islets; #p<0.05 vs. F islets. 









